Astera Labs (NASDAQ:ALAB) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Astera Labs from “hold” to “buy,” while analyst opinions remain mixed: MarketBeat reports 13 Buy and 10 Hold ratings, with a “Moderate Buy” consensus and an average price target of $320.85.
• Astera Labs beat quarterly estimates, reporting EPS of $1.32 versus $1.19 expected and revenue of $584.9 million versus $550.8 million expected; revenue rose 153.6% year over year.
• Some brokerages have cut ratings or price targets amid valuation and growth concerns, even as other analysts remain positive. Shares were reported at $190.71, well below their 50-day moving average of $300.46.

Astera Labs (NASDAQ:ALAB - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other brokerages have also recently issued reports on ALAB. Zacks Research cut shares of Astera Labs from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 5th. Citigroup cut shares of Astera Labs from a "buy" rating to a "hold" rating in a research report on Friday, October 9th. Roth Capital restated a "buy" rating and issued a $450.00 price objective on shares of Astera Labs in a report on Wednesday, August 5th. Susquehanna decreased their price target on Astera Labs from $310.00 to $258.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, TD Cowen dropped their price target on shares of Astera Labs from $300.00 to $225.00 and set a "hold" rating for the company in a research report on Wednesday. Thirteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $320.85.

Astera Labs Trading Up 6.3%

ALAB stock opened at $190.71 on Friday. The firm has a market capitalization of $33.09 billion, a PE ratio of 148.17 and a beta of 3.85. The firm has a 50-day moving average of $300.46 and a two-hundred day moving average of $255.80. Astera Labs has a one year low of $97.89 and a one year high of $499.48.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.13. The firm had revenue of $584.90 million during the quarter, compared to analysts' expectations of $550.78 million. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The company's revenue for the quarter was up 153.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.49 earnings per share. On average, equities research analysts anticipate that Astera Labs will post 2.71 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Manuel Alba sold 183,000 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $280.13, for a total transaction of $51,263,790.00. Following the sale, the director owned 253,863 shares of the company's stock, valued at approximately $71,114,642.19. This represents a 41.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jitendra Mohan sold 90,630 shares of Astera Labs stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $340.35, for a total value of $30,845,920.50. Following the completion of the sale, the chief executive officer owned 1,266,665 shares of the company's stock, valued at $431,109,432.75. The trade was a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 396,059 shares of company stock worth $123,408,470 over the last ninety days. 10.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Astera Labs

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Astera Labs during the second quarter worth approximately $6,609,581,000. Atreides Management LP increased its stake in Astera Labs by 108.9% during the 1st quarter. Atreides Management LP now owns 3,365,787 shares of the company's stock valued at $368,890,000 after buying an additional 1,754,593 shares during the period. Van ECK Associates Corp lifted its stake in Astera Labs by 20.0% during the second quarter. Van ECK Associates Corp now owns 2,237,961 shares of the company's stock valued at $1,080,980,000 after buying an additional 373,545 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Astera Labs during the second quarter worth $1,061,791,000. Finally, Amundi boosted its position in Astera Labs by 77.9% during the first quarter. Amundi now owns 1,880,830 shares of the company's stock worth $206,139,000 after purchasing an additional 823,477 shares during the period. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Astera Labs reported Q3 revenue of $584.9 million, up 154% year over year, and its Scorpio switch business was highlighted as a major growth driver. One Seeking Alpha contributor upgraded the stock, citing Scorpio’s momentum and gross margins that may stabilize near 72%. Astera Labs: So Much To Like In Q3 (Upgrade)
• Positive Sentiment: BMO Capital initiated coverage with an Outperform rating and a $375 price target; Northland Securities also upgraded the stock to Outperform. These calls provide a counterpoint to recent selling and valuation worries. BMO Capital Initiates Coverage on Astera Labs With Outperform Rating Astera Labs Upgraded to Outperform at Northland Securities
• Neutral Sentiment: Analyst views remain divided, with one recent opinion arguing that the selloff may already reflect a potential growth slowdown in 2027. Astera Labs: Sell-Off Already Priced In 2027 Stall
• Negative Sentiment: A reported analyst downgrade triggered renewed pressure, while coverage also points to ALAB’s rich valuation after its Q3 results. Those concerns may amplify selling when technology stocks are broadly weak. Shares Gap Down After Analyst Downgrade Stock Drops After Q3 Results Spotlight Rich Valuation
• Negative Sentiment: Astera Labs was caught in a wider technology-sector selloff, adding market-wide pressure beyond company-specific news. Astera Labs Falls Amid Tech Selloff

Astera Labs Company Profile

Astera Labs, Inc is a fabless semiconductor company that develops connectivity solutions for cloud and artificial intelligence infrastructure. Its products are designed to help move data among processors, accelerators, memory and other components in high-performance computing systems.

The company's portfolio includes Aries PCIe and CXL retimers, Taurus Ethernet smart cable modules, Scorpio fabric switches and Leo CXL memory connectivity controllers. Astera Labs also offers software tools to help customers configure and monitor its connectivity products.

Founded in 2017 and headquartered in Santa Clara, California, Astera Labs serves the global cloud and computing markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.